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A B S T R A C T
Periodontitis is a common chronic inﬂammatory condition that results in increased levels of inﬂammatory cy-
tokines and inﬂammatory mediators. In addition to oral disease and tooth loss, it also causes low-grade systemic
inﬂammation that contributes to development of systemic conditions including cardiovascular disease, pre-term
birth, diabetes and cancer. Chronic inﬂammation is associated with epigenetic change, and it has been suggested
that such changes can alter cell phenotypes in ways that contribute to both ongoing inﬂammation and devel-
opment of associated pathologies. Here we show that exposure of human gingival ﬁbroblasts to IL-1β increases
expression of maintenance methyltransferase DNMT1 but decreases expression of de novo methyltransferase
DNMT3a and the demethylating enzyme TET1, while exposure to PGE2 decreases expression of all three en-
zymes. IL-1β and PGE2 both aﬀect global levels of DNA methylation and hydroxymethylation, as well as me-
thylation of some speciﬁc CpG in inﬂammation-associated genes. The eﬀects of IL-1β are independent of its
ability to induce production of PGE2, and the eﬀects of PGE2 on DNMT3a expression are mediated by the EP4
receptor. The ﬁnding that exposure of ﬁbroblasts to IL-1β and PGE2 can result in altered expression of DNA
methylating/demethylating enzymes and in changing patterns of DNA methylation suggests a mechanism
through which inﬂammatory mediators might contribute to the increased risk of carcinogenesis associated with
inﬂammation.
1. Introduction
Periodontal disease is a common cause of tooth loss in the US and
around the world [1,2], and is recognized as a contributing factor in a
variety of systemic conditions [3–6]. Bacteria are required to initiate
the disease, but host factors are critical for the development of chronic
inﬂammation, which is characterized by an imbalance between in-
ﬂammatory and anti-inﬂammatory cytokines. Increased levels of in-
ﬂammatory cytokines, especially IL-1β, activate gingival ﬁbroblasts to
produce matrix metalloproteinases, chemokines and other in-
ﬂammatory mediators, including prostaglandin E2 (PGE2), which
contribute to both continuing inﬂammation and to degradation of tis-
sues supporting teeth [5–8]. The presence of periodontitis has been
associated with development of serious health conditions, including
cardiovascular disease [9], pre-term birth [10], diabetes [11] and
several types of cancer [12–15]. Periodontal pathogens have been
found in distant tissues and could be directly involved in development
or progression of some of these conditions [3,16–18], but the presence
of chronic, low-grade systemic inﬂammation associated with period-
ontal disease may also be important [19,20].
Modiﬁcation of CpG DNA by methylation (producing 5-methylcy-
tosine, 5mC), constitutes an important epigenetic signal that has vital
roles in maintaining genomic stability and regulating gene expression.
DNA methylation is established by de novo methyltransferases DNMT3a
and 3b, and maintained during DNA replication by the maintenance
methylase DNMT1. The Ten Eleven Translocation (TET1-3) family of
dioxygenase enzymes can reverse DNA methylation through successive
oxidation of 5mC to 5 hydroxymethylcytosine (5hmC), 5-for-
mylcytosine (5fC) and 5-carboxylcytosine (5caC), which can then be
removed passively or actively through DNA repair pathways. Although
DNA methylation is especially important for stable suppression of gene
expression during development and diﬀerentiation, recent evidence
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shows that 5mC and 5hmC can also play important roles in more dy-
namic types of gene regulation, including in some cases transcriptional
activation (reviewed in [21]).
Changes in patterns of DNA methylation are a common feature of
cancer cells, with 5mC levels decreased globally but increased in the
promoters of certain genes. Global hypomethylation contributes to
genomic instability, while hypermethylation in promoters generally
inhibits transcription and is a common mechanism for inactivation of
Fig. 1. IL-1β and PGE2 aﬀect expression of DNMT1, DNMT3a and TET1. (A and C) Total RNA was isolated from untreated HGF cells (control) or cells treated for 24 h
with IL-1β or PGE2 at the indicated doses. (B and D) RNA was isolated at the indicated times after addition of IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM). mRNA
levels of DNMT1, DNMT3a and TET1 were determined by real-time PCR. (E) Whole cell lysates were isolated from HGF cultures that were untreated (control) or
treated for 24 h with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM). DNMT1 and DNMT3a protein levels were determined by ELISA. Graphs show mRNA or protein
levels expressed relative to untreated controls as box and whisker plots showing interquartile ranges, with the mean marked by X. At least three diﬀerent HGF cell
lines derived from diﬀerent donors were used in each experiment. Statistical signiﬁcance (*p < 0.05, **p < 0.01) vs untreated control was determined by One-way
ANOVA followed by Dunnett’s test for multiple comparisons.
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tumor suppressor genes. The ﬁnding that DNA methylation patterns are
similarly (though less severely) disrupted in chronically inﬂamed tis-
sues [22–26], has led to the hypothesis that inﬂammatory signals create
an “inﬂammatory milieu” that over time might result in epigenetic
changes in aﬀected tissues, causing altered gene expression patterns
and contributing to both the persistence of inﬂammation and to the
predisposition to cancer [27,28]. However, it is still unclear whether or
how inﬂammatory signals initiate the epigenetic changes.
The current series of experiments was undertaken to determine
whether exposure of primary cultures of human gingival ﬁbroblasts
(HGF) to inﬂammatory cytokine IL-1β, or inﬂammatory mediator
PGE2, results in altered expression or activity of enzymes involved in
DNA methylation/demethylation.
2. Materials and methods
2.1. Cell culture
Human gingival tissue samples were obtained with informed con-
sent and without any identifying information from patients receiving
treatment for periodontitis. Samples were processed by enzymatic dis-
persion to produce primary cell cultures, as described previously
[29,30]. Cells were maintained in Eagle’s Minimal Essential Medium
(EMEM) supplemented with 10% fetal bovine serum and antibiotic/
antimycotic (penicillin, streptomycin, amphotericin; Gibco/BRL). Cells
between passages 3 and 5 were used for experiments. At least three
diﬀerent HGF primary cell lines, each derived from a diﬀerent donor,
were used for each experiment. Cells were treated with IL-1β
(0.1–100 ng/ml (5.7 × 10−3–5.71 μM); Sigma), or PGE2 (0.1–100 μM;
Sigma) for the indicated times. COX-2 inhibitor NS398 (0.1 μM, Sigma)
was added to cells 1 h prior to addition of IL-1β and incubation for
another 24 h. Agonists to prostanoid receptors EP1-4 (Iloprost, Buta-
prost, Sulprostone, and CAY10598) were obtained from Cayman Che-
micals and used at 0.1 or 10 μM for 24 h. EP4 receptor antagonist
ONOAE3208 (0.01 μM, R&D Systems) was added 1 h prior to addition
of IL-1β or PGE2, followed by incubation for another 24 h.
2.2. RNA isolation and analysis
Total RNA was isolated from HGF cells using the RNeasy Plus Micro
Kit (Qiagen). Two ug total RNA was converted to cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystem) and a
TC300 Thermal Cycler (Techne). Two µl cDNA was used with TaKaRa
Premix Ex Taq (Clonetech), and probes for detection of DNMT1 (FAM-
MGB Hs00945875_m1), DNMT3a (FAM-MGB Hs01027166_m1), TET1
(FAM-MGB Hs04189347_g1), IL-8 (FAM-MGB Hs00174103_m1), CD40
(FAM-MGB Hs01002915_g1), or TNFRSF10C (FAM-MGB
Hs00182570_m1), along with Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH, product limiting, VIC-MGB PL
Hs0275891_g1); all obtained from Applied Biosystem. Real Time PCR
was performed using the Applied Biosystem StepOne Plus Real Time
PCR system. Reactions were performed in quadruplicate with both the
target gene and endogenous control in the same well. Results were
calculated as 2−ΔCT, normalizing to GAPDH, and expressed relative to
untreated control.
2.3. Determination of DNMT1 and DNMT3a protein levels
Whole cell lysate isolated from HGF that were untreated (Controls)
or treated with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 24 h
were analyzed using the Human DNMT3a or DNMT1 ELISA kits
(LifeSpan BioSciences). The colorimetric assays were read using the
BioRad iMark MicroPlate Reader at 450 nm.
2.4. Determination of global levels of 5mC and 5hmC
DNA was isolated from HGF that were untreated (Controls) or
treated with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 24, 48 or
72 h using the FitAmp Blood and Cultured Cell DNA Extraction Kit
(EpiGenTek). The MethylFlash Methylated DNA 5-mC Quantiﬁcation
Kit or the MethylFlash Hydroxymethylated DNA 5-hmC Quantiﬁcation
Kit (EpiGenTek) were used to quantitate 5mC and 5hmC, respectively.
The colorimetric assays were read using the BioRad iMark MicroPlate
Reader at 450 nm.
2.5. Determination of 5mC levels at speciﬁc CpG
DNA was isolated from two diﬀerent HGF cell lines which were
untreated (Controls) or treated with IL-1β (10 ng/ml, 0.57 μM) or PGE2
(100 μM) for 48 h using the FitAmp Blood and Cultured Cell DNA
Fig. 2. IL-1β and PGE2 aﬀect global levels of 5mC and 5hmC. Global levels of
5mC (A) and 5hmC (B) were determined by MethylFlash ELISA-like assays
using DNA isolated from HGF that were untreated (control) or treated with IL-
1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 24, 48 or 72 h. Graphs show
percent 5mC or 5hmC expressed relative to untreated controls, as box and
whisker plots showing interquartile ranges, with the mean marked by X. Five
diﬀerent HGF cell lines derived from diﬀerent donors were used. Statistical
signiﬁcance (*p < 0.05, **p < 0.01) vs untreated control was determined by
One-way ANOVA followed by Dunnett’s test for multiple comparisons. Global
levels of 5hmC were lower as compared to 5mC, but in the range expected
based on other studies [75,79].
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Extraction Kit (EpiGenTek). Targeted Next Generation Bisulﬁte
Sequencing was performed by EpigenDx, Inc., Hopkinton, MA using
their pre-validated immunology panel, with the addition of CpG targets
in IL-8, MMP-1, MMP-3 and MMP-13 promoters. The multiplex PCR
conditions were optimized for the new targets, then seven multiplex
PCRs were performed on the DNA templates provided, which had been
treated with bisulﬁte using the EZ DNA methylation Kit (Zymo
Research). Products were pooled and puriﬁed using QIAquick PCR
Puriﬁcation columns (Qiagen), then libraries were made using the
KAPA Library Preparation Kit for Torrent Platforms and In Xpress
Barcode adaptors (Thermo Fisher). Library molecules were puriﬁed
using Agencourt AMPure XP beads and quantiﬁed using the Qiagen
QIAxcel Advanced system. Barcoded samples were pooled in an equi-
molar fashion and templates prepared and enriched using the Ion Chef
system (Thermo Fisher). Template-positive library molecules were se-
quenced on the Ion S5 sequencer using Ion 530 sequencing chips
(Thermo Fisher). FASTQ ﬁles from the Ion Torrent S5 server were
aligned to the local reference database using Bismark Bisulﬁte Read
Mapper and the Bowtie2 program. Methylation levels were calculated
as a percentage of methylated reads as compared to total number of
reads. Only CpG sites covered by a minimum of 100 total reads were
considered. An R-square value of> 0.9 was required for validation.
2.6. Determination of PGE2 levels
PGE2 levels in conditioned media from untreated control cultures or
cultures treated with IL-1β (10 ng/ml, 0.57 μM) and/or NS398 (0.1 μM)
for 24 h were determined using the Prostaglandin E2 Parameter Assay
Kit (R&D Systems) according to the manufacturer’s suggested protocol.
The colorimetric assay was read at 450 nm in a BioRad iMark micro-
plate reader and values were determined from the standard curve.
2.7. Statistical analysis
Statistical signiﬁcance was determined by One-way or Two-way
analysis of variance (ANOVA) followed by Dunnett, Bonferroni or
Tukey tests for multiple comparisons using GraphPad Prism 7.05 soft-
ware. Comparisons with adjusted p values less than 0.05 were con-
sidered statistically signiﬁcant.
3. Results
3.1. IL-1β and PGE2 aﬀect expression of DNMT1, DNMT3a and TET1
Treatment of HGF with IL-1β for 24 h caused statistically signiﬁcant
increased expression of DNMT1 mRNA, while decreasing expression of
DNMT3a and TET1 (Fig. 1A). In order to show the degree of variation
among the diﬀerent HGF cell lines used (at least three for each ex-
periment, and each derived from a diﬀerent donor), the data was
plotted to show the interquartile range of results, with X marking the
mean. This shows that the response of DNMT1 mRNA to IL-1β showed
greater variation among cell lines as compared to DNMT3a and TET1,
in which the magnitude of response sometimes varied but the direction
was always the same (with some exception at the lowest doses). Ten ng/
ml (0.57 μM) IL-1β was used for further study because it gave consistent
results across multiple HGF cell lines without signs of toxicity, and was
used previously to study the eﬀects of IL-1β on gene expression in HGF
[29,31–35]. Incubation of HGF cell cultures with 10 ng/ml IL-1β over
time showed that, on average, IL-1β signiﬁcantly increased DNMT1
mRNA within 12–24 h, with a concomitant decrease in expression of
DNMT3a and TET1 which began as early as 3 h (Fig. 1B).
Since IL-1β is known to increase production of PGE2 through the
action of cyclo-oxygenase 2 (COX-2) in HGF [29,30], and since PGE2
Table 1
Eﬀect of IL-1β or PGE2 treatment on DNA methylation at speciﬁc CpG.
Gene CpG# Percent Methylated DNA
HGF1 HGF2
Control IL-1β (fold) PGE2 (fold) Control IL-1β (fold) PGE2 (fold)
CD40 34 4.0 4.1 (1.0) 5.8 (1.5) 8.9 14.3 (1.6) 14.8 (1.7)
33 4.1 3.7 (0.9) 5.8 (1.4) 5.7 5.2 (0.9) 5.9 (1.0)
32 1.0 2.2 (2.2) 2.8 (2.8) 2.2 1.8 (0.8) 4.8 (2.2)
31 3.2 3.2 (1.0) 3.8 (1.2) 9.6 12.9 (1.3) 16.1 (1.7)
30 2.9 3.7 (1.3) 5.8 (2.0) 4.3 4.9 (1.1) 6.1 (1.4)
29 0.4 1.3 (3.3) 1.4 (3.5) 2.6 3.5 (1.3) 2.4 (0.9)
28 4.8 8.2 (1.7) 9.8 (2.0) 7.6 7.4 (1.0) 6.6 (0.9)
27 3.3 2.6 (0.8) 1.7 (0.5) 3.7 4.5 (1.2) 3.7 (1.0)
26 5.5 4.4 (0.8) 4.0 (0.7) 13.6 8.9 (0.7) 11.1 (0.8)
IL-8 5 26.4 25.2 (1.0) 25.6 (1.0) 37.0 39.6 (1.1) 40.7 (1.1)
4 4.6 6.4 (1.4) 8.0 (1.7) 10.5 9.8 (0.9) 10.9 (1.0)
3 3.8 2.4 (0.6) 2.1 (0.6) 0.9 0.3 (0.3) 1.4 (1.6)
TNFRSF10C 20 57.7 61.7 (1.1) 57.4 (1.0) 47.6 46.0 (1.0) 41.8 (0.9)
19 26.9 37.0 (1.4) 30.0 (1.1) 26.8 31.9 (1.2) 30.9 (1.2)
18 28.5 28.0 (1.0) 25.3 (0.9) 15.2 19.8 (1.3) 22.6 (1.5)
17 36.4 40.6 (1.1) 41.9 (1.2) 46.8 51.7 (1.1) 47.6 (1.0)
16 45.8 51.6 (1.1) 60.3 (1.3) 55.8 59.0 (1.1) 56.6 (1.0)
15 24.1 25.1 (1.0) 27.5 (1.1) 37.5 36.4 (1.0) 36.5 (1.0)
14 16.6 17.7 (1.1) 17.3 (1.0) 32.4 35.4 (1.1) 29.7 (0.9)
13 31.0 31.2 (1.0) 32.4 (1.0) 26.0 29.5 (1.1) 32.0 (1.2)
12 13.9 16.0 (1.2) 11.8 (0.8) 23.4 27.5 (1.2) 22.5 (1.0)
11 9.6 10.9 (1.1) 10.4 (1.1) 12.3 12.3 (1.0) 14.5 (1.2)
MMP13 4 19.5 25.1 (1.3) 26.2 (1.3) 25.5 27.7 (1.1) 27.9 (1.1)
3 46.2 52.2 (1.1) 49.4 (1.1) 36.7 41.4 (1.1) 40.0 (1.1)
2 48.8 52.6 (1.1) 50.5 (1.0) 45.2 49.3 (1.1) 49.31.1)
Two diﬀerent HGF cell lines were left untreated (Control) or treated with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 48 h. Isolated DNA was analyzed by
targeted next-generation bisulﬁte sequencing. Methylation levels were calculated by dividing the number of methylated reads by the total number of reads. Only CpG
sites covered by at least 100 reads were considered. The table shows genes from the analysis that had a least one site exhibiting a change in methylation of at least
20% in treated vs untreated control cells. Changes of 20% or more are bold.
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has been shown to aﬀect expression of DNMTs in other systems [36,37],
the eﬀect of PGE2 on expression of these enzymes was also assessed.
Results (Fig. 1C and D) show that PGE2 caused a decrease in expression
of both DNMT1 and DNMT3a, as well as TET1 mRNA. One hundred μM
PGE2 gave consistent results across multiple HGF cell lines without
signs of toxicity and was used for further study. Although the magni-
tude of response varied among the cell lines, all three genes were
consistently and signiﬁcantly decreased, and this occurred as early as
3 h. In accordance with the mRNA results, protein levels of DNMT1
were increased by IL-1β but decreased by PGE2, and DNMT3a was
decreased by both IL-1β and PGE2 at 24 h (Fig. 1E), though again the
magnitude of response of DNMT1 to IL-1β was more variable. Protein
levels of TET1 were below the limit of detection by this method and
could not be accurately determined.
3.2. IL-1β and PGE2 aﬀect global levels of 5mC and 5hmC, as well as
methylation of speciﬁc sites in the promoters of inﬂammation-associated
genes
In order to determine whether changes in levels of the enzymes
were functionally signiﬁcant, global levels of DNA methylation and
hydroxymethylation were assessed in HGF cells treated with IL-1β
(10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 24, 48 or 72 h. Global levels
of 5mC were signiﬁcantly increased by both IL-1β and PGE2, but the
magnitude of the response, especially to IL-1β, was decreased by 72 h
(Fig. 2a). Global levels of 5hmC were also increased by both IL-1β and
PGE2, but whereas the IL-1β increase was maintained for at least 72 h,
the eﬀects of PGE2 was more transient (Fig. 2B).
Targeted next generation bisulﬁte sequencing was performed in
order to determine whether speciﬁc changes in DNA methylation in the
promoters of inﬂammation-associated genes occurred in response to IL-
1β and/or PGE2 (Epigendx). Two diﬀerent HGF cell lines were treated
with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 48 h, and levels
of DNA methylation at speciﬁc CpG sites were compared to untreated
controls. Results of this analysis are shown in Table 1. Basal levels of
DNA methylation at the speciﬁc CpG tested often diﬀered between the
cell lines, but the changes in response to IL-1β and PGE2 were usually
similar. Among the genes showing changes in DNA methylation of at
least 20% at one or more CpG in both cell lines were: CD40, IL-8, and
TNFRSF10C. DNA methylation at the following sites was increased or
decreased by 20% or more in both cell lines by IL-1β and/or by PGE2:
CpG 34, 32, 31, 30, 29, and 26 in the CD40 promoter; CpG3 in the IL-8
promoter; and CpG 19 and 12 in the TNFRSF10C promoter. Methylation
at most of these sites was increased, but methylation of CpG 26 of CD40
and CpG3 of IL-8 was decreased. Genes included in the analysis that did
not show changes in methylation at the CpG sites examined included:
CDKN2A, IL1B, IL2, IL4, IL7, IL7R, IL13, TNFA, TNFRSF25, MMP1 and
MMP3.
Fig. 3. Eﬀects of IL-1β and PGE2 on mRNA expression of genes that showed changes in methylation at speciﬁc CpG in their promoters. Total RNA was isolated from
HGF cultures that were untreated (control) or treated with IL-1β (10 ng/ml, 0.57 μM) or PGE2 (100 μM) for 24 or 48 h. mRNA levels of IL-8 (A and B) and CD40 and
TNFRSF10C (C and D) were determined by real-time PCR and expressed relative to levels in untreated controls. Graphs show data from three diﬀerent HGF cell
cultures derived from three diﬀerent donors, with mRNA levels expressed relative to untreated controls and depicted in box and whisker plots showing interquartile
ranges, with the mean marked by X. Statistical signiﬁcance (*p < 0.05, **p < 0.01) vs untreated control was determined by One-way ANOVA followed by
Dunnett’s test for multiple comparisons.
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The eﬀects of IL-1β and PGE2 stimulation on expression of IL-8,
CD40 and TNFRSFC10 mRNA in HGF was examined in order to de-
termine whether the changes in methylation of their promoters could
be correlated with changes in gene expression. IL-8 mRNA expression in
HGF was increased by both IL-1β and PGE2 (Fig. 3 A and B) as has been
previously reported [38–40], while expression of CD40 and
TNFRSF10C was decreased (Fig. 3 C and D).
3.3. Eﬀects of IL-1β are not dependent on COX-2-mediated increased
production of PGE2
IL-1β is known to induce COX-2-mediated production of PGE2 in
many cell types, including HGF [29,30]. In order to determine whether
the eﬀects of IL-1β on expression of DNMTs and TET1 are mediated by
PGE2, cells were pre-treated with COX-2 inhibitor NS-398 prior to ad-
dition of IL-1β. As expected based on previous data [29,30], IL-1β
signiﬁcantly increased production of PGE2 in HGF, though the amount
at baseline and the magnitude of increase varied among cells from
diﬀerent donors. Treatment with NS-398 inhibited the IL-1β induction
and resulted in PGE2 levels not signiﬁcantly diﬀerent from untreated
controls (Fig. 4A). However, the eﬀects of IL-1β on expression of
DNMT1, DNMT3a and TET1 mRNA were unchanged by addition NS-
398 (Fig. 4B). These results suggest that IL-1β can aﬀect expression of
these enzymes independently of its ability to increase PGE2 production.
3.4. Eﬀects of PGE2 on DNMT1, DNMT3a and TET1 expression in HGF
are mimicked by an agonist of the EP4 receptor
The eﬀects of PGE2 on gene expression are often cell-type and
condition speciﬁc, due in part to diﬀering levels of expression of its four
receptors, EP1-4, which activate diﬀerent signal transduction pathways
by activating diﬀerent G proteins [41,42]. HGF cell cultures were
treated with agonists of each of the four receptors to determine which
EP receptor(s) are involved in PGE2-mediated inhibition of DNMTs and
TET1 expression (Fig. 5). Only the EP4 agonist CAY10598 resulted in
decreased expression of all three genes. DNMT3a expression was sig-
niﬁcantly decreased in response to the EP4 agonist CAY10598, but
unaﬀected by the other three agonists (Fig. 5). Expression of DNMT1
and TET1 were also decreased by the EP4 agonist, but their patterns
were somewhat more complicated. DNMT1 inhibition by CAY10598
required a higher dose, and DNMT1 mRNA expression was also sig-
niﬁcantly increased by the EP3 agonist sulprostone. TET1 mRNA levels
were decreased by 1 μM CAY10598 to a level similar to that seen with
PGE2, but signiﬁcantly increased by 10 μM, and TET1 expression was
also decreased by the higher dose of sulprostone.
In order to conﬁrm the role of the EP4 receptor in mediating the
eﬀects of PGE2 and the PGE2-independent eﬀects of IL-1β on DNMT3a
expression, HGF were pre-treated with EP4 receptor antagonist
ONOAE3208 prior to addition of IL-1β or PGE2. As expected, the EP4
receptor antagonist prevented PGE2 inhibition of DNMT3a mRNA ex-
pression, but had no eﬀect on decreased expression caused by IL-1β
(Fig. 6). The antagonist also did not alter the eﬀect of IL-1β on DNMT1
or TET1 expression. However, it abrogated the eﬀects of PGE2 in only
one of four HGF cell lines (data not shown).
4. Discussion
Results of these experiments show that IL-1β and PGE2 can not only
aﬀect expression of epigenetic modiﬁers (Fig. 1), but they can also af-
fect both global and site-speciﬁc patterns of DNA methylation (Fig. 2
and Table 1). These results are consistent with the idea that epigenetic
changes play an important role in periodontitis pathology, and poten-
tially in the increased risk of cancer associated with it. A recent study by
Planello et al [26] found that the DNA methylation patterns in gingival
tissue of patients with chronic periodontitis were signiﬁcantly diﬀerent
from healthy controls, but had much in common with the DNA me-
thylation alterations found in oral squamous cell carcinomas. The au-
thors suggest that the epigenetic changes seen in the chronically in-
ﬂamed tissues represent a pre-neoplastic state. The ﬁnding that IL-1β
and PGE2 are able to aﬀect expression of enzymes that regulate DNA
methylation, as well as levels of 5mC and 5hmC in gingival ﬁbroblasts,
supports this notion and provides a clue to how these changes might be
initiated.
Treatment of HGF cultures with IL-1β caused a transient increase in
global levels of 5mC with a more sustained increase in 5hmC levels
(Fig. 2). Eﬀects of PGE2 were similar, although levels of 5mC were still
signiﬁcantly above control levels at 72 h. Since IL-1β caused an increase
in DNMT1 expression while PGE2 caused a decrease, these results
suggest that levels of DNMT1 may not be the most important factor in
determining global levels of 5mC. It is important to remember,
Fig. 4. IL-1β eﬀects on gene expression are not altered by inhibition of COX-2
mediated PGE2 production. HGF cell cultures were untreated (control) or pre-
treated with NS398 (0.1 μM) for 1 h before addition of IL-1β (10 ng/ml,
0.57 μM). Conditioned media and total RNA were harvested 24 h after addition
of IL-1β. (A) PGE2 levels in conditioned media were determined by
Prostaglandin E2 Parameter Assay Kit (R&D Systems). (B) DNMT1, DNMT3a
and TET1 mRNA levels were determined by real-time PCR and expressed re-
lative to untreated control. Graphs show data from three to ﬁve diﬀerent HGF
cell lines derived from diﬀerent donors, expressed relative to untreated con-
trols, as box and whisker plots showing interquartile ranges, with the mean
marked by X. Statistical signiﬁcance (**p < 0.01 vs untreated control,
$p < 0.05 vs IL-1β alone)) was determined by Two-way ANOVA followed by
Tukey’s test for multiple comparisons. There was no statistical signiﬁcance
detected in comparison of PGE2 levels in IL-1 + NS398 vs control or vs Ns398
alone; and also no signiﬁcant diﬀerence in mRNA levels between IL and 1+
NS389 vs IL-1 alone.
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however, that global levels of DNA methylation/hydroxymethylation
are determined by the combined eﬀects of multiple epigenetic eﬀectors.
For example, it has been suggested that one of the roles of TET1 is to
protect CpG sites from inappropriate methylation [43]. This might
provide a partial explanation both for the increase in global DNA me-
thylation and for the fact that most of the site-speciﬁc methylation
changes observed in response to IL-1β or PGE2 were increased me-
thylation. Interestingly, a recent study by O’Neill et al [44] showed that
depletion of DNMT1 in normal human ﬁbroblasts resulted in increased
methylation of a substantial number of sites. In addition, inﬂammation
is also associated with changes in histone modiﬁcations, which may be
involved in the disruption of DNA methylation patterns. In a mouse
colitis model, changes in patterns of H3K27me3 were seen in colonic
epithelial cells exposed to inﬂammatory conditions, and some of those
changes were linked to later changes in DNA methylation [45].
Despite diﬀerent eﬀects on DNMT1 levels, IL-1β and PGE2 aﬀected
DNA methylation at mostly the same sites, and usually in the same
direction (Table 1). Of the inﬂammation-related genes examined, three
(CD40, IL-8, TNFRSF10C) had CpG sites whose levels of methylation
changed at least 20% following treatment with IL-1β or PGE2 for 48 h
in both cell lines tested. Methylation of CpG 19 in the TNFRSF10C
promoter was increased 20–40% by IL-1β, and nearly 20% by PGE2.
This gene encodes Decoy Receptor 1 (DCR1, TRAILR3), a negative
regulator of apoptosis induced by TRAIL (tumor necrosis factor-related
apoptosis-induced ligand) [46]. Its expression is decreased in a variety
of cancer cells due to hypermethylation [47–50] and this was linked to
increased binding of DNMT1 and DNMT3a to the promoter in malig-
nant melanoma cells [49]. Consistent with these ﬁndings, both IL-1β
and PGE2 decreased expression of TNFRSF10C in HGF (Fig. 3).
CD40 is a co-stimulatory molecule required for activation of antigen
presenting cells, and binding of CD40L in those cells induces expression
of cytokines and chemokines [51]. CD40 is also expressed on en-
dothelial cells and ﬁbroblasts, and its expression in ﬁbroblasts was
shown to be increased by IFNγ and related to cell proliferation [52]. In
HGF, CD40 crosslinking was shown to inhibit both basal and IL-1β in-
duced production of matrix metalloproteinases 1 and 3 [53]. As shown
in Fig. 3, IL-1β and PGE2 both decreased mRNA expression of CD40
(Fig. 3). However, since treatment with IL-1β and PGE2 increased DNA
methylation of some CpG sites in the CD40 promoter while decreasing
methylation of others, further study would be needed to determine
whether changes in mRNA expression can be linked to speciﬁc changes
in DNA methylation. Interestingly, several of the sites that showed in-
creased methylation are in transcription factor binding sites [54–57].
Although many transcription factors bind preferentially to hypo-
methylated sites, some prefer methylated binding sites [58].
Increased expression of IL-8 [38,40] is an established part of the
Fig. 5. EP receptor agonists aﬀect expression of DNMT1, DNMT3a and TET1. HGF cultures were left untreated (control) or treated for 24 h with the indicated doses
(0.1 or 10 μM) of selective agonists to (A) EP1 (Iloprost), (B) EP2 (Butaprost), (C) EP3 (Sulprostone), and D) EP4 (CAY10598). Levels of DNMT1, DNMT3a, and TET1
mRNA were determined by real-time PCR and expressed relative to untreated controls. Graphs show data expressed relative to untreated controls, as box and whisker
plots showing interquartile ranges, with the mean marked by X. At least three diﬀerent HGF cell lines from diﬀerent donors were used for each experiment. Statistical
signiﬁcance (*p < 0.05, **p < 0.01) vs untreated control was determined by Two-way ANOVA with post-hoc Tukey test for multiple comparisons.
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response of gingival ﬁbroblasts to inﬂammatory mediators. Our results
conﬁrmed that both IL-1β and PGE2 increased expression of IL-8 mRNA
(Fig. 3A and B). IL-1β increased IL-8 expression to a variable extent,
ranging from 4 to over 200-fold compared to the untreated control,
while PGE2 caused a more modest but consistent increase. The ﬁnding
that methylation of CpG 3 in the IL-8 promoter was decreased (Table 1)
is consistent with other studies showing that the IL-8 promoter is hy-
pomethylated in periodontitis [59,60]. Also, Venza et al. [57] showed
that PGE2 caused decreased methylation at CpG3 (−83) in astrocytoma
cells, and this was linked to increased binding of CEBPβ and decreased
association of DNMT1 and DNMT3a to the site.
This is, to our knowledge, the ﬁrst report of TET1 mRNA expression
in HGF. However, the mRNA levels were quite low and protein levels
could not be easily detected, so the relevance of this ﬁnding is unclear.
Both IL-1β and PGE2 did consistently decrease TET1 mRNA levels in all
HGF cultures tested, however. They also caused a signiﬁcant increase in
global levels of 5hmC (Fig. 2), although in the case of PGE2 this eﬀect
was transient. It has been reported that TET1 and TET2 act pre-
ferentially on 5mC residues as compared to 5hmC or 5fC [61]. Thus, the
initial increase in 5hmC may reﬂect a stabilization of 5hmC due to
inability to completely oxidize it to 5fC and 5caC when TET levels are
decreased. The subsequent decrease at 72 h might then reﬂect passive
loss of 5hmC over continued time in culture.
Although the role of 5hmC in gene regulation is still not well un-
derstood [43,62], decreased levels of TET1 and 5hmC are frequently
seen in tumors, and these changes are considered poor prognostic in-
dicators in several types of cancer [63–65]. Some evidence suggests that
decreased TET activity may be involved in initiation of carcinogenesis
[66–68], including a study in transgenic mice that linked COX-2 over-
expression, which was associated with increased production of PGE2
and decreased TET1 levels, with spontaneous development of hepato-
cellular carcinoma [66].
Since IL-1β and PGE2 resulted in similar decreases in DNMT3a and
TET1 expression (Fig. 1), and since previous results from this laboratory
[29,30] and others [69,70] have shown that IL-1β induces COX-2
mediated PGE2 production in HGF, it was important to determine
whether the eﬀects of IL-1β were determined by its ability to induce
production of PGE2. Although inhibition of COX-2 did result in de-
creased levels of PGE2 production, there was no change in the ability of
IL-1β to cause changes in DNMT1, DMT3a or TET1 expression (Fig. 4).
These results suggest that PGE2 and IL-1β are operating through dif-
ferent, though possibly overlapping pathways. Although treatment of
HGF with PGE2 itself caused decreased expression of DNMT1, as did
stimulation of the EP4 receptor with CAY10958 (albeit at a higher dose
than required for DNMT3a), the EP3 receptor agonist increased DNMT1
mRNA expression (Fig. 5). Thus it appears likely that the ﬁnal net eﬀect
of PGE2 on DNMT1 expression includes both stimulation via EP3 and
suppression via EP4. This complexity probably also explains the in-
ability of the EP4 antagonist to consistently abrogate the eﬀect of PGE2
on DNMT1 expression. The fact that suppression by EP4 seems to
dominate most of the time might be explained by diﬀerences in the
relative levels of the receptors and/or by diﬀerent aﬃnities of the re-
ceptors for PGE2. The aﬃnities of recombinant EP receptors for PGE2
have been reported as EP3 > EP4 > EP2 > EP1 [71], but levels of
EP3 on HGF are reported to be low [8,71]. Although cell surface ex-
pression of the receptors was not formally addressed in this study,
mRNAs encoding all four receptors were easily detected (not shown).
The ability of an EP4 receptor antagonist to abrogate the eﬀects of
PGE2 on expression of DNMT3a (Fig. 6) conﬁrm the importance of EP4
at least in this case, but further research is needed to fully elucidate the
signaling pathway(s) that are activated.
The eﬀects of IL-1β and PGE2 on expression of the DNMTs and TET
might be mediated at the transcriptional or post-transcriptional level.
Transcription factors known to aﬀect expression of DNMT1, DNMT3a
and/or TET include: NF-κB, AP-1, p53, RB/E2F, STAT3 and Sp1 and
Sp3 (reviewed in [72,73]). DNMT1 induction by IL-1β and TNFα in
adipocytes [74], and IL-1β inhibition of TET1 expression in chon-
drocytes [75] was linked to NF-κB. However, levels of all three enzymes
can also be controlled at the post-transcriptional level by micro-RNAs
[72,73] and some of these have been reported to be up-regulated in
periodontitis-aﬀected tissues [76]. For example, miR-29 directly targets
TET1 and DNMT3a [77], and is up-regulated in gingival tissue in per-
iodontitis [78]. Further experiments are needed to determine the mo-
lecular mechanisms involved in regulation of these enzymes by in-
ﬂammatory mediators.
Menendez and Alarcon [28] suggested that cells respond to infec-
tion or stress by activating an inﬂammatory response that creates a
transient state of “epigenetic plasticity” that allows cells to make tem-
porary changes to their phenotype in order to restore tissue home-
ostasis. However, if the state of epigenetic plasticity goes on too long, it
can interfere with the repair process and create a cancer-like state. Our
ﬁndings suggest that exposure of ﬁbroblasts to inﬂammatory cytokines
and mediators such as PGE2 might contribute to this plasticity by af-
fecting the expression and/or activity of enzymes directly involved in
regulating epigenetic signals.
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Fig. 6. An EP4 receptor antagonist blocks the eﬀect of PGE2 on expression of
DNMT3a. HGF cultures were pre-treated with EP4 receptor antagonist
ONOAE3208 (0.01 μM) for one hour before addition of IL-1β (10 ng/ml,
0.57 μM) or PGE2 (100 μM) for 24 h. Levels of DNMT3a mRNA were de-
termined by real-time PCR and expressed relative to untreated controls. Four
diﬀerent HGF cell lines derived from diﬀerent donors were used. The graph
shows data in box and whisker plots showing interquartile ranges, with the
mean marked by X. Statistical signiﬁcance (**p < 0.01 vs untreated control, $
$p < 0.01 vs PGE2 alone) was determined by Two-way ANOVA with post-hoc
Tukey. No statistical signiﬁcance was detected between IL-1+antagonist vs IL-1
alone, or between control vs PGE2+antagonist.
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